hematologic neoplasms

Summary

Summary: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Top Publications

  1. ncbi Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients
    Donatella Baronciani
    Unità Operativa Ematologia e Centro Trapianti Wilma Deplano Ospedale Oncologico Armando Businco, Cagliari
    Am J Hematol 83:717-20. 2008
  2. ncbi Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation
    Agostinho Carvalho
    Microbiology, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy
    Exp Hematol 37:1022-9. 2009
  3. ncbi Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia
    C Y Chen
    Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Epidemiol Infect 138:1044-51. 2010
  4. ncbi The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
    Livio Pagano
    Istituto di Ematologi, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Rome, Italy
    Haematologica 91:1068-75. 2006
  5. ncbi The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy
    Ray Hachem
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2493-9. 2008
  6. ncbi Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006
    C Bosetti
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Ann Oncol 19:29-43. 2008
  7. ncbi Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
    Georgios Chamilos
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Infect Dis 47:503-9. 2008
  8. ncbi Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
  9. ncbi Invasive fungal infections in hematology: new trends
    R Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Av Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Ann Hematol 81:233-43. 2002
  10. ncbi Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries
    Michael Hauptmann
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:1615-23. 2003

Research Grants

  1. GENETIC ANALYSIS OF POLARITY
    Ruth Steward; Fiscal Year: 2009
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
  3. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2010
  4. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
  5. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
  6. Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
    Catalina Lawsin; Fiscal Year: 2007
  7. AUTOMATED CLOSED SYSTEM FOR DMSO REMOVAL FROM PERIPHERAL BLOOD STEM CELLS
    ERIK WOODS; Fiscal Year: 2007
  8. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo Luo; Fiscal Year: 2009
  9. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo R Luo; Fiscal Year: 2010
  10. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    M Golam Mohi; Fiscal Year: 2009

Detail Information

Publications305 found, 100 shown here

  1. ncbi Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients
    Donatella Baronciani
    Unità Operativa Ematologia e Centro Trapianti Wilma Deplano Ospedale Oncologico Armando Businco, Cagliari
    Am J Hematol 83:717-20. 2008
    ..Longer follow-up and further prospective studies are necessary to evaluate this regimen...
  2. ncbi Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation
    Agostinho Carvalho
    Microbiology, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy
    Exp Hematol 37:1022-9. 2009
    ..Discovery of genetic variations in the genes encoding for Toll-like receptors (TLRs) has highlighted a potential link between genomic variation of the host and susceptibility to infections...
  3. ncbi Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia
    C Y Chen
    Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    Epidemiol Infect 138:1044-51. 2010
    ..calcoaceticus-baumannii complex and vancomycin-resistant enterococci were also found during the study period. Emerging antimicrobial resistant pathogens are an increasing threat to neutropenic cancer patients...
  4. ncbi The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
    Livio Pagano
    Istituto di Ematologi, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1, I 00168 Rome, Italy
    Haematologica 91:1068-75. 2006
    ..The aim of this study was to evaluate the incidence and outcome of invasive fungal infections (IFI) in patients with hematologic malignancies...
  5. ncbi The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy
    Ray Hachem
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:2493-9. 2008
    ..The objective of the current retrospective study was to compare the epidemiology of candidemia and its risk factors in patients who had hematologic malignancies(HM) with those in patients who had solid tumors (ST)...
  6. ncbi Formaldehyde and cancer risk: a quantitative review of cohort studies through 2006
    C Bosetti
    Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
    Ann Oncol 19:29-43. 2008
    ..Occupational exposure to formaldehyde has been associated with excess risk of nasopharyngeal and selected other cancers...
  7. ncbi Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis
    Georgios Chamilos
    Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Infect Dis 47:503-9. 2008
    ..Zygomycosis is an emerging opportunistic mycosis among immunocompromised patients with a particularly poor prognosis...
  8. ncbi Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality
    Arlo Upton
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Clin Infect Dis 44:531-40. 2007
    ..The aim of this study was to determine the probability of survival and prognostic factors associated with outcomes over a long period of time...
  9. ncbi Invasive fungal infections in hematology: new trends
    R Martino
    Division of Clinical Hematology, Hospital de la Sant Creu i Sant Pau, Av Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Ann Hematol 81:233-43. 2002
    ..However, the exact place of these agents in treating different IFI will need to be found in the near future...
  10. ncbi Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries
    Michael Hauptmann
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    J Natl Cancer Inst 95:1615-23. 2003
    ..We extended follow-up of a cohort of industrial workers to evaluate the association between formaldehyde exposure and lymphohematopoietic cancers...
  11. ncbi NKG2D gene polymorphism has a significant impact on transplant outcomes after HLA-fully-matched unrelated bone marrow transplantation for standard risk hematologic malignancies
    J Luis Espinoza
    Department of Hematology and Oncology, Kanazawa University Hospital, 13 1 Takaramachi, Kanazawa, 920 8641, Japan
    Haematologica 94:1427-34. 2009
    ....
  12. ncbi Sinus surgery combined with antifungal therapy is effective in the treatment of invasive Aspergillus sinusitis in neutropenic patients with cancer
    R Y Hachem
    Dept of Infectious Diseases, Infection Control and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Infection 36:539-42. 2008
    ..Invasive Aspergillus sinusitis (IAS) is associated with high mortality and poor response to antifungal therapy in patients with hematologic malignancies (HM)...
  13. ncbi Granzymes A and B serum levels in allo-SCT
    B Kircher
    Department of Internal Medicine V Hematology and Oncology, Immunobiology and Stem Cell Laboratory, Innsbruck Medical University, Innsbruck, Austria
    Bone Marrow Transplant 43:787-91. 2009
    ..Similar effects were observed with GrB. In conclusion, Gr protein levels can also be used as a marker for complications after Allo-SCT...
  14. ncbi FISH analysis of hematological neoplasias with 1p36 rearrangements allows the definition of a cluster of 2.5 Mb included in the minimal region deleted in 1p36 deletion syndrome
    Idoya Lahortiga
    Laboratory of Genetics, Division of Oncology, Center for Applied Medical Research CIMA, University of Navarra, Pio XII, 55, 31080, Pamplona, Spain
    Hum Genet 116:476-85. 2005
    ..5 Mb of the complete 1p36 band. This could explain its proneness for involvement in chromosomal rearrangements in hematological neoplasias...
  15. ncbi Platelet alloimmunization in multitransfused patients with haemato-oncological disorders
    Meenu Bajpai
    Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
    Natl Med J India 18:134-6. 2005
    ..Testing for the presence of antiplatelet antibodies and provision of compatible platelets should be important components in the management of patients with platelet transfusion refractoriness...
  16. ncbi Neurologic complications of hematologic neoplasms
    Lawrence Recht
    Department of Neurology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA
    Neurol Clin 21:87-105. 2003
    ..This article summarizes such complications that occur as a result of direct infiltration or compression of nervous tissue by tumor or as a result of indirect effects such as infection, vascular disorders, iatrogenesis, and paraneoplasia...
  17. ncbi Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections
    M J Vasconcelles
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 6:35-43. 2000
    ....
  18. ncbi Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    J Clin Oncol 23:3923-31. 2005
    ..To determine the safety, dosing schedules, pharmacokinetic profile, and biologic effect of orally administered histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with advanced cancer...
  19. ncbi The fundamental role of epigenetics in hematopoietic malignancies
    Oliver Galm
    Medizinische Klinik IV, Universitaetsklinikum Aachen, 52074 Aachen, Germany
    Blood Rev 20:1-13. 2006
    ..The ongoing exploration of basic events involved in altered gene transcription patterns and continued clinical investigative studies are helping to develop novel strategies for the diagnosis, prevention, and treatment of human cancer...
  20. ncbi Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort
    Laura E Beane Freeman
    Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Natl Cancer Inst 101:751-61. 2009
    ....
  21. ncbi Mitochondrial DNA in human malignancy
    J S Penta
    Office of Clinical Research, National Institute of Environmental Health Sciences, National Institutes of Health, P O Box 12233, MD A2 05, Research Triangle Park, NC 27709, USA
    Mutat Res 488:119-33. 2001
    ..Finally, we examine the role of reactive oxygen species (ROS) generated by mitochondria in the process of carcinogenesis...
  22. ncbi Family history of hematopoietic malignancy and risk of lymphoma
    Ellen T Chang
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    J Natl Cancer Inst 97:1466-74. 2005
    ....
  23. ncbi Recent developments in the management of invasive fungal infections in patients with hematological malignancies
    Meinolf Karthaus
    Medizinische Klinik II, Evangelisches Johannes Krankenhaus, Schildescher Strasse 99, 33611 Bielefeld, Germany
    Ann Hematol 84:207-16. 2005
    ..This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients...
  24. ncbi Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data
    ZiYi Lim
    Haematological Medicine, Kings College London and Kings College Hospital, London, UK
    Br J Haematol 136:448-50. 2007
    ..10%, P = 0.19). None of the nine myeloablative HSCT recipients survived (median survival: 9 d). Six of the 15 reduced-intensity conditioned HSCT recipients survived beyond 1 year (median survival: 1050 d, range: 438-1437)...
  25. ncbi Tumor infiltration of bone marrow in patients with hemato-logical malignancies: dynamic contrast-enhanced magnetic resonance imaging
    Lei Zhang
    Department of Radiology, Tongji Hospital of Tongji University, Shanghai 200065, China
    Chin Med J (Engl) 119:1256-62. 2006
    ....
  26. ncbi Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU
    B Lamia
    Kremlin Bicetre University Hospital, Medical Intensive Care Department, 78 rue du General Leclerc, 94270 Le Kremlin Bicetre, France
    Intensive Care Med 32:1560-8. 2006
    ..To determine whether severity and organ failure scores over the first 3 days in an ICU predict in-hospital mortality in onco-hematological malignancy patients...
  27. ncbi Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants
    Andrew Daly
    Allogeneic Bone Marrow Transplant Program, Princess Margaret Hospital University Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Biol Blood Marrow Transplant 9:373-82. 2003
    ..We conclude that a quantitative T-cell deficiency in these extensively T-cell depleted patients may be a risk factor for infection, even in the absence of graft-versus-host disease...
  28. ncbi Optimistic expectations and survival after hematopoietic stem cell transplantation
    Stephanie J Lee
    Department of Medical Oncology, and Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 9:389-96. 2003
    ..Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation...
  29. ncbi Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Owen A O'Connor
    Department of Medicine, Division of Hematologic Oncology, Lymphoma Service, Memorial Sloan Kettering Cancer Center, Sloan Kettering Institute, New York, NY 10021, USA
    J Clin Oncol 24:166-73. 2006
    ..To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies...
  30. ncbi Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously
    Wm Kevin Kelly
    Genitourinary Oncology Service, Departments of Medicine, Memorial Sloan Kettering Cancer Center and Joan and Sanford Weill Medical College of Cornell University, New York, New York 10021, USA
    Clin Cancer Res 9:3578-88. 2003
    ..To evaluate the safety, pharmacokinetics, and biological activity of suberoylanilide hydroxamic acid (SAHA) administered by 2-h i.v. infusion in patients with advanced cancer...
  31. ncbi Hypermethylation of gene promoters in hematological neoplasia
    C S Chim
    University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong
    Hematol Oncol 20:167-76. 2002
    ..Emerging evidence suggests a possible prognostic value of gene promoter hypermethylation. Moreover, gene hypermethylation may also serve as a target for therapeutic invention by hypomethylating agents...
  32. ncbi Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies
    Elias J Anaissie
    Myeloma Institute for Research and Treatment, University of Arkansas for Medical Sciences, Little Rock 72205, USA
    Blood 101:2542-6. 2003
    ..Hospital water distribution systems may serve as a potential indoor reservoir of Aspergillus and other molds leading to aerosolization of fungal spores and potential exposure for patients...
  33. ncbi Prognosis of hematologic malignancies does not predict intensive care unit mortality
    Paul B Massion
    Department of Critial Care Medicine, Cliniques Universitaires de Mont-Godinne, , Yvoir, Belgium
    Crit Care Med 30:2260-70. 2002
    ..Therefore, reluctance to admit patients with nonterminal hematologic malignancies to the intensive care unit based only on the prognosis of their underlying hematologic malignancy does not seem justified...
  34. ncbi Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study
    Christian Junghanss
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Biol Blood Marrow Transplant 8:512-20. 2002
    ..This risk is an important consideration for the future development of preventive strategies...
  35. ncbi Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies
    D Valcarcel
    Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Eur J Haematol 74:144-51. 2005
    ..Nevertheless, high mortality rates may be associated with this therapy, especially in older patients, those with other comorbidities or who receive a second HSCT...
  36. ncbi Incidence and outcome of critical illness amongst hospitalised patients with haematological malignancy: a prospective observational study of ward and intensive care unit based care
    A C Gordon
    Department of Anaesthesia and Intensive Care, Barts and the London Queen Mary's School of Medicine and Dentistry, St. Bartholomew's Hospital, West Smithfield, London, EC1A 7BE, UK
    Anaesthesia 60:340-7. 2005
    ..There was close agreement between actual and predicted mortality with increasing Simplified Acute Physiology Score II for all patients, including those not admitted to intensive care...
  37. ncbi Effects of an exercise program on muscle performance in patients undergoing allogeneic bone marrow transplantation
    M Mello
    Clinical Hospital of University of São Paulo, Sao Paulo Brazil
    Bone Marrow Transplant 32:723-8. 2003
    ..In trial 3, TG showed values higher than CG for all muscle groups tested. These results suggest that the exercise program was efficient in promoting an increase of muscle strength after allogeneic BMT...
  38. ncbi A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease
    Xiao Jun Huang
    Peking University Institute of Hematology, People s Hospital, Beijing 100044, China
    Chin Med J (Engl) 117:1778-85. 2004
    ..We developed a new technique for HLA mismatched allogeneic HSCT using G-CSF primed bone marrow plus G-CSF-mobilized peripheral blood stem cells without ex vivo T cell depletion...
  39. ncbi Bone marrow transplantation in the course of hematological malignancies--follow-up study in blood serum by 31P MRS
    Małgorzata Kuliszkiewicz-Janus
    Department of Hematology, Wrocław University of Medicine, Poland
    Med Sci Monit 10:CR485-92. 2004
    ..Bone marrow transplantation (BMT) is one of the most efficient methods for the treatment of hematological neoplasms. Its successful application requires previous complete remission (CR) and exclusion of residual disease...
  40. ncbi Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation
    J Vela-Ojeda
    Hematology Department, Stem Cell Transplant Program, Unidad Medica de Alta Especialidad Antonio Fraga Mouret National Medical Center La Raza, Instituto Mexicano del Seguro Social, Mexico, DF, Mexico
    Ann Hematol 85:113-20. 2006
    ..In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT...
  41. ncbi A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation
    M J Hjermstad
    Department of Behavioural Sciences in Medicine, University of Oslo, Norway
    Bone Marrow Transplant 34:257-66. 2004
    ..This suggests a need for a closer follow-up of these patients with special emphasis on functional status and fatigue...
  42. ncbi Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors
    Razvan Diaconescu
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
    Blood 104:1550-8. 2004
    ..In conclusion, nonmyeloablative regimens had lower RRT and NRM and could be considered for comparative studies, including younger patients with more favorable Charlson comorbidity scores...
  43. ncbi Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:961-8. 2004
    ..After adjustment for pretransplantation differences between the 2 patient groups, the hazard ratio was 3.0 (P=.04). Multivariate analyses showed higher pretransplantation comorbidity scores to result in increased toxicity and mortality...
  44. ncbi Role of epigenetic changes in hematological malignancies
    Ulrich Lehmann
    Institute of Pathology, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625, Hannover, Germany
    Ann Hematol 83:137-52. 2004
    ..In addition, the implications for therapy and prognosis will be discussed...
  45. ncbi Role of depression as a predictor of mortality among cancer patients after stem-cell transplantation
    Jesús M Prieto
    Department of Psychiatry, Clinical Institute of Psychiatry and Psychology, University of Barcelona, Spain
    J Clin Oncol 23:6063-71. 2005
    ..To determine the association between depression and survival among cancer patients at 1, 3, and 5 years after stem-cell transplantation (SCT)...
  46. ncbi Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  47. ncbi Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation
    D H Kim
    Department of Hematology/Oncology, Kyungpook National University Hospital, 50 Samduk 2-Ga, Jung-gu, Daegu 700-721, Korea
    Bone Marrow Transplant 37:1119-28. 2006
    ..In a multivariate analysis, rapid recovery of CD4+ helper T cells at 3 months was a favorable prognostic factor together with higher CD34+ cell transplant dose in terms of OS (P=0.001) and NRM (P=0.005)...
  48. ncbi Australasian haematologist referral patterns to palliative care: lack of consensus on when and why
    K Auret
    School of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
    Intern Med J 33:566-71. 2003
    ..Patients with haematological malignancies are not referred to palliative care services as frequently as those with solid cancers (non-haematological malignancies)...
  49. ncbi Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies
    H Nakajima
    Division of Hematology/Medical Oncology, Tokai University School of Medicine, Boseidai, Isehara, Japan
    Clin Lab Haematol 25:383-91. 2003
    ..A further study in large-scale setting is warranted...
  50. ncbi Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning
    Avichai Shimoni
    Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Acta Haematol 112:93-104. 2004
    ..Immunotherapy is more effective for MRD than at frank relapse. Timing and dosing of therapy are not yet well established and depend on aggressiveness of the disease, type of conditioning, level and kinetics of MRD...
  51. ncbi Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors
    Jyotsna Reddy
    Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390, USA
    Oncogene 24:732-6. 2005
    ....
  52. ncbi Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg
    Manel Esteller
    Cancer Epigenetics Laboratory, Spanish National Cancer Center CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
    Clin Immunol 109:80-8. 2003
    ..Furthermore, promising studies using DNA demethylating agents and histone deacetylase inhibitors are underway to awake these dormant tumor-suppressor genes for a better treatment of the patient with a hematologic malignancy...
  53. ncbi Outcome of hemato-oncologic patients with and without stem cell transplantation in a medical ICU
    T Bruennler
    Department of Internal Medicine, University of Regensburg, Germany
    Eur J Med Res 12:323-30. 2007
    ..To assess the outcome of a mixed population of critical ill patients with haematological malignancies with special focus on the comparison of patients who underwent stem cell transplantation with non-transplanted patients...
  54. ncbi Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
    Scott C Kogan
    Comprehensive Cancer Center and Department of Laboratory Medicine, University of California, San Francisco, 94143, USA
    Blood 100:238-45. 2002
    ..This classification will be of particular value to investigators seeking to develop, use, and communicate about mouse models of human hematopoietic neoplasms...
  55. ncbi Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse
    Ibrahim Yakoub-Agha
    Service des Maladies du Sang, UAM allogreffes de CSH, CHU, Lille, France
    Biol Blood Marrow Transplant 15:496-504. 2009
    ....
  56. ncbi Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies
    Xing Hua Chen
    Department of Hematology, Internal of Field Battle, Xinqiao Hospital, The Third Military Medical University, Chongqing, 400037, PR China
    Biol Blood Marrow Transplant 15:266-73. 2009
    ..In conclusion, it is a feasible approach with acceptable outcomes for patients undergoing HLA-haploidentical related HSCT by the combination of G-PBSCs and G-BM with conditioning regimens including ATG...
  57. ncbi Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication
    Dominique D Benoit
    Department of Intensive Care, Ghent University Hospital, Gent, Belgium
    Crit Care Med 31:104-12. 2003
    ..To assess the outcome and to identify early prognostic indicators in a global population of patients with hematologic malignancy admitted to the intensive care unit for a life-threatening complication...
  58. ncbi JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
    Amy V Jones
    Wessex Regional Genetics Laboratory, Salisbury, UK
    Nat Genet 41:446-9. 2009
    ..7; 95% CI = 3.1-4.3) and provides a model whereby a constitutional genetic factor is associated with an increased risk of acquiring a specific somatic mutation...
  59. ncbi The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan
    Ryoji Kobayashi
    Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan
    J Pediatr Hematol Oncol 30:886-90. 2008
    ..AML was most strongly associated using a multivariate analysis. The prognosis of IFI has been expected poor; therefore, prevention of this condition, especially for older patients with AML, would be important...
  60. ncbi Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors
    J Evison
    Dept. of Internal Medicine, Kantonsspital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
    Swiss Med Wkly 131:681-6. 2001
    ..CONCLUSION: Multi-organ failure and evidence of liver damage but no other patient, disease, or treatment related factor predict outcome in patients with haematological disease admitted to the ICU...
  61. ncbi Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies
    Jutta Auberger
    Department of Internal Medicine, Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
    Int J Hematol 88:508-15. 2008
    ..7, P = 0.018). A significant decrease in fungus-related deaths was observed despite a significant increase of IFI over time, probably due to improved diagnostic and therapeutic approaches...
  62. ncbi Flow cytometric immunophenotyping for hematologic neoplasms
    Fiona E Craig
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, PA, USA
    Blood 111:3941-67. 2008
    ..remains an indispensable tool for the diagnosis, classification, staging, and monitoring of hematologic neoplasms. The last 10 years have seen advances in flow cytometry instrumentation and availability of an expanded ..
  63. ncbi Immune reconstitution after autologous hematopoietic stem cell transplantation
    L F Porrata
    Department of Oncology, Mayo Cinic, Rochester, Minn. 55905, USA
    Mayo Clin Proc 76:407-12. 2001
    ....
  64. ncbi Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia
    D Caillot
    Department of Clinical Hematology, University Hospital of Dijon, Dijon, France
    J Clin Oncol 19:253-9. 2001
    ..In patients with neutropenia, thoracic computed tomography (CT) halo and air-crescent signs are recognized as major indicators of invasive pulmonary aspergillosis (IPA). Nevertheless, the exact timing of CT images is not well known...
  65. ncbi Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    S Giralt
    Department of Blood and Bone Marrow Transplantation and Biomathematics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Blood 97:631-7. 2001
    ..In summary, fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population...
  66. ncbi World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
    N L Harris
    Departments of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 17:3835-49. 1999
    ....
  67. ncbi A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms
    Outi Kilpivaara
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Nat Genet 41:455-9. 2009
    ..We found that JAK2(V617F) is preferentially acquired in cis with the predisposition allele. These data suggest that germline variation is an important contributor to MPN phenotype and predisposition...
  68. ncbi Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation
    J Cavet
    University Department of Haematology, School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom
    Blood 98:1594-600. 2001
    ..Assessment of cytokine genotype may potentially allow more accurate prediction of GVHD and appropriate adjustment of GVHD prophylaxis, as well as indicating novel areas for future studies of GVHD pathogenesis...
  69. ncbi A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia
    Peter Gimsing
    Department of Hematology, Finsen Center, University Hospital Rigshospitalet, Copenhagen, Denmark
    Eur J Haematol 81:170-6. 2008
    ..To determine the safety, dose-limiting toxicity and maximum tolerated dose (MTD) of the novel hydroxamate histone deacetylase inhibitor belinostat (PXD101) in patients with advanced hematological neoplasms...
  70. ncbi A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms
    Damla Olcaydu
    Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
    Nat Genet 41:450-4. 2009
    ..Thus, disease susceptibility loci may harbor somatic mutations that have a role in disease pathogenesis...
  71. ncbi lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells
    Lei Wu
    Celgene Corporation, Summit, New Jersey 07901, USA
    Clin Cancer Res 14:4650-7. 2008
    ....
  72. ncbi Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis
    Jose A Perez-Simon
    Servicio de Hematologia, Hospital Clinico Universitario de Salamanca, Salamanca, Spain
    Biol Blood Marrow Transplant 14:664-71. 2008
    ..Regarding GVHD, this combination allowed to control aGVHD but lead to a high incidence of cGVHD, so that newer strategies are required, especially in trying to decrease gastrointestinal involvement...
  73. ncbi Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect
    R K Dasgupta
    Department of Haematology, University Hospital Aintree, Liverpool, UK
    Bone Marrow Transplant 37:455-61. 2006
    ..Further studies are required to confirm these findings...
  74. ncbi Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation
    Francis Ayuk
    Department of Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany
    Biol Blood Marrow Transplant 14:913-9. 2008
    ..A prospective randomized study comparing these 2 doses of ATG-F is warranted...
  75. ncbi Bleeding complications after hematopoietic stem cell transplantation
    Markus Pihusch
    Bone Marrow Transplantation Unit, 1st Department of Internal Medicine, University of Regensburg, Germany
    Semin Hematol 41:93-100. 2004
    ..The role of recombinant FVIIa as a hemostatic agent for the treatment of HSCT-associated hemorrhage will be briefly explored...
  76. ncbi Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation
    Y Asano
    Department of Cell Therapy and Transplantation Medicine, University of Tokyo Hospital, Tokyo, Japan
    Bone Marrow Transplant 32:1175-9. 2003
    ..Male predominance was detected in LHC after HSCT, as has been previously shown in children with AdV-induced acute HC. The detection of AdV DNA in serum did not predict a poor outcome...
  77. ncbi [Non-myeloablative transplant of hematopoietic precursor cells. Myth and reality]
    David Gomez-Almaguer
    Servicio de Hematologia, Hospital Universitario de la UANL Dr José E González, Monterrey, NL
    Rev Invest Clin 57:291-7. 2005
    ..This kind of transplant is making real progress in the world of transplantation...
  78. ncbi A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease
    K B Miller
    Department of Medicine, Bone Marrow Transplantation and Hematological Malignancy Unit, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Bone Marrow Transplant 33:881-9. 2004
    ..This novel reduced intensity preparative regimen was well tolerated and associated with a low incidence of transplant-related mortality and serious acute and cGVHD...
  79. ncbi [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands]
    E J Petersen
    Universitair Medisch Centrum Utrecht, afd Hematologie huispost G 03 647, Heidelberglaan 100, 3584 CX Utrecht
    Ned Tijdschr Geneeskd 147:2328-32. 2003
    ..To describe the results of allogeneic stem cell transplantation after non-myeloblative conditioning in high-risk patients with a haematological malignancy...
  80. ncbi Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis
    J Schetelig
    , , , Berlin, Germany
    Bone Marrow Transplant 33:483-90. 2004
    ....
  81. ncbi Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity
    Wolfgang A Bethge
    Medical Center, University of Tuebingen, Tuebingen, Germany
    Exp Hematol 34:1746-52. 2006
    ....
  82. ncbi Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution
    C Martinez
    Transplantation Unit, Department of Hematology, Postgraduate School of Hematology Farreras Valenti, Institute of Hematology and Oncology, IDIBAPS Hospital Clinic, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Leuk Res 25:379-84. 2001
    ..However, the procedure is associated with a high transplant-related mortality. Better results might be obtained by carefully selecting patients and by reducing the intensity of the preparative regimen...
  83. ncbi Impact of chimaerism analysis and kinetics on allogeneic haematopoietic stem cell transplantation outcome after conventional and reduced-intensity conditioning regimens
    Anne Sophie Michallet
    Department of Haematology, Edouard Herriot Hospital, Lyon 69437, France
    Br J Haematol 128:676-89. 2005
    ..4% for PMC (P < 0.0001 and P < 0.0001). Multivariate analysis only showed a significant impact of chimaerism status on OS, as well as acute and chronic graft-versus-host disease on EFS, with a trend for conditioning regimen...
  84. ncbi [Outcome of allogeneic stem cell transplantation for hematological disorders in patients older than 50]
    Katsumichi Fujimaki
    Central Sterile Ward, Yokohama City University Hospital
    Gan To Kagaku Ryoho 32:47-51. 2005
    ..08). For patients receiving RIST without complete remission, relapse and infection were the main causes of death. Our data suggest that patients without complete remission should receive CST to the degree possible...
  85. ncbi Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors
    Takanori Teshima
    Centre for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
    Br J Haematol 130:575-87. 2005
    ..RICT from a one-locus-mismatched donor may represent an effective alternative approach in patients with high-risk malignancies who lack HLA-matched related donors...
  86. ncbi Second allografts for relapsed hematologic malignancies: feasibility of using a different donor
    J E Duus
    Bone Marrow Transplant Program, Department of Internal Medicine, Loyola University Medical Center, Stritch School of Medicine, Maywood, IL 60153, USA
    Bone Marrow Transplant 35:261-4. 2005
    ..There were no cases of transplant-related mortality. We conclude that a second allogeneic HSCT using a different donor is a viable option for selected patients relapsing after an allograft if the original donor is not available...
  87. ncbi A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  88. ncbi Severe metabolic abnormalities after allogeneic hematopoietic cell transplantation
    J H Lee
    Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 388 1 Poongnap 2 dong, Songpa Ku, Seoul 138 736, Korea
    Bone Marrow Transplant 35:63-9. 2005
    ....
  89. ncbi Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT)
    A S Michallet
    Service d Hematologie Clinique, Hopital Edouard Herriot, Lyon Cedex, France
    Bone Marrow Transplant 35:601-8. 2005
    ..A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation...
  90. ncbi Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease
    Martin Schmidt-Hieber
    Medizinische Klinik III Hämatologie, Onkologie und Transfusionsmedizin, Charite Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Br J Haematol 130:568-74. 2005
    ..We conclude that basiliximab is efficient and feasible for steroid-refractory aGVHD and merits further evaluation...
  91. ncbi Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation
    Andrea Bacigalupo
    Dipartimento di Emato Oncologia, Ospedale San Martino, Genoa, Italy
    Haematologica 89:1238-47. 2004
    ..The aims of this study were to determine whether these relationships still hold and whether the outcome of transplants is continuing to improve...
  92. ncbi [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]
    J Casper
    Abteilung Hämatologie und Onkologie der Medizinischen Fakultät der Universität Rostock
    Dtsch Med Wochenschr 130:2125-9. 2005
    ..We have, therefore, developed a dose intense but toxicity reduced conditioning regimen based on treosulfan and fludarabine and report first results...
  93. ncbi Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation
    R Srinivasan
    Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD 20892-1652, USA
    Br J Haematol 131:74-9. 2005
    ..Membranous nephropathy resulting in NS is a previously unrecognised and clinically significant complication of non-myeloablative HCT...
  94. ncbi Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients
    M Y Shapira
    Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Bone Marrow Transplant 34:155-9. 2004
    ..Our data suggest that RIC-allo-SCT may be safely applied in the elderly, suggesting that allogeneic immunotherapy may become an important tool for treatment of hematological malignancies without an age limit...
  95. ncbi Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning
    Frederic Baron
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 104:2254-62. 2004
    ..02). Measuring the levels of peripheral blood cell subset donor chimerisms provided useful information on HCT outcomes and might allow early therapeutic interventions to prevent graft rejection or disease progression...
  96. ncbi Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen
    P Frere
    Department of Medicine, Division of Haematology, University of Liege, Liege, Belgium
    Bone Marrow Transplant 37:411-8. 2006
    ..In conclusion, after NMSCT, infections are not frequent in the first 30 days post transplant but careful long-term monitoring is necessary thereafter...
  97. ncbi Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation
    Chirag R Parikh
    University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Am J Kidney Dis 45:502-9. 2005
    ..The present study compares the incidence of ARF between patients undergoing concurrent myeloablative and nonmyeloablative HCT in the same period at the same institution...
  98. ncbi Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation
    Hirohisa Nakamae
    Clinical Hematology and Clinical Diagnostics, Graduate School of Medicine, Osaka City University, Osaka, Japan
    Am J Hematol 81:525-31. 2006
    ..Our results also showed that high-dose Bu (16 mg/kg) for the conditioning and FK506 for the prophylaxis of GVHD might contribute more significantly to TMA onset after HSCT than other agents...
  99. ncbi Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007
    ..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens...
  100. ncbi Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy
    John E Levine
    Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan 48109 0914, USA
    Biol Blood Marrow Transplant 9:189-97. 2003
    ..A reduction in conditioning intensity is associated with poor survival for patients with advanced-stage disease, highlighting the importance of the conditioning regimen for tumor control...
  101. ncbi Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
    ..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype...

Research Grants101 found, 100 shown here

  1. GENETIC ANALYSIS OF POLARITY
    Ruth Steward; Fiscal Year: 2009
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  2. GENETIC ANALYSIS OF POLARITY
    RUTH M STEWARD; Fiscal Year: 2010
    ..We are aiming at developing a PCR approach to differentiate between the forms of PDCD2 found in normal bone marrow and blood, and the PDCD2 forms associated with leukemic cells. ..
  3. Targeting aberrant epigenetics by nanomedicine
    Shujun Liu; Fiscal Year: 2010
    ....
  4. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2010
    ..We anticipate that these approaches will cure more patients and cause fewer toxicities than currently available therapies. ..
  5. Post-transplant vaccines to enhance graft-versus-leukemia responses
    CATHERINE JU YING WU; Fiscal Year: 2010
    ..End of Abstract) ..
  6. Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
    Catalina Lawsin; Fiscal Year: 2007
    ....
  7. AUTOMATED CLOSED SYSTEM FOR DMSO REMOVAL FROM PERIPHERAL BLOOD STEM CELLS
    ERIK WOODS; Fiscal Year: 2007
    ..The goal of this research is to produce a device to easily remove DMSO from PBSC before they are transplanted, increasing effectiveness of the cells and reducing potential complications. ..
  8. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo Luo; Fiscal Year: 2009
    ..In addition, although we focus on neutropenia-related pneumonia in this application, the same strategy can be readily applied to other neutropenia-related infectious diseases. ..
  9. Enhancing neutrophil function in neutropenia-related pneumonia
    Hongbo R Luo; Fiscal Year: 2010
    ..In addition, although we focus on neutropenia-related pneumonia in this application, the same strategy can be readily applied to other neutropenia-related infectious diseases. ..
  10. Role of JAK2V617F in the Pathogenesis of Myeloproliferative Disorders.
    M Golam Mohi; Fiscal Year: 2009
    ..The results of these studies may identify new therapeutic targets for MPDs. Moreover, our inducible JAK2V617F knock-in mouse will provide a unique and reproducible animal model to test novel therapies for JAK2V617F-associated MPDs. ..
  11. Histone Deacetylase Inhibition: A Novel Approach to Cardioprotection
    Ting C Zhao; Fiscal Year: 2010
    ....
  12. Genome Wide Admixture Scan for Multiple Myeloma in African Americans
    CHRISTOPHER ALAN HAIMAN; Fiscal Year: 2010
    ..Our ultimate goal is to reduce the health disparity experienced by African Americans due to this fatal cancer. ..
  13. The Molecular Pathology of Myeloproliferative Disease
    Jonathan Licht; Fiscal Year: 2007
    ..abstract_text> ..
  14. A novel method for identification of minor histocompatibility antigens
    Brad Stone; Fiscal Year: 2007
    ..Efficient identification of these target proteins will allow development of treatments that will modify transplants to promote the beneficial, curative GVL effect, while minimizing harmful GVHD responses. ..
  15. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  16. NUCLEOSIDE AND NUCLEOTIDE METABOLIZING ENZYMES
    Beverly Mitchell; Fiscal Year: 1999
    ....
  17. Inosine Monophosphate Dehydrogenase: Regulation and Function
    Beverly Mitchell; Fiscal Year: 2007
    ..abstract_text> ..
  18. Transcriptional Functions and Targets of the MMSET Protein of t(4:14) Myeloma
    Jonathan D Licht; Fiscal Year: 2010
    ..These data lead to our overarching hypothesis that aberrant overexpression of MMSET leads to deregulated gene expression in B cells, contributing to the pathogenesis of myeloma. ..
  19. ADHESION MOLECULES MEDIATING SKIN TROPISM IN ACUTE GVHD
    Robert Sackstein; Fiscal Year: 2003
    ....
  20. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2007
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. ..
  21. Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
    Warren D Shlomchik; Fiscal Year: 2010
    ..Unfortunately, for reasons that are unknown, many cancers are resistant to this therapy and this proposal will investigate the biology underlying this differential sensitivity. ..
  22. Phase I study of 8-Cl-adenosine in CLL (IND 68,229)
    Varsha Gandhi; Fiscal Year: 2009
    ..The investigators state that these Aims will establish utility of 8-Cl-Ado in CLL, provide a dose for Phase 2 study, and knowledge for optimal use of this agent alone and in combination. ..
  23. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..2A. To evaluate a panel of cytokines as surrogate markers for GVHD and correlate these with clinical outcomes during the above trial. 2B. To correlate changes in minimal residual disease with clinical outcomes during the above trial. ..
  24. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..We will test all these hypotheses by collecting individual-patient data on each outcomes of interest from the existing data sets (i.e. from published and unpublished randomized studies) using the techniques of SR/MA. ..
  25. Genetic Manipulation of T Cells--PreClinical Models
    John Dipersio; Fiscal Year: 2005
    ..Issues regarding the use of genetically manipulated T-cells to control GvHD can best be investigated through the use of informative animal models and the comprehensive studies described in this proposal. ..
  26. ROLE OF THE G-CSF RECEPTOR IN PROGENITOR MOBILIZATION
    Daniel C Link; Fiscal Year: 2011
    ..We believe this research will lead to novel strategies to mobilized blood stem cells for transplantation, enhance engraftment of stem cells after transplantation, and potential treat leukemia. ..
  27. High Performance Magnetic Cell Sorting
    JEFFREY CHALMERS; Fiscal Year: 2006
    ..abstract_text> ..
  28. DLI using genetically modified T cells: Phase 1 trial
    John Dipersio; Fiscal Year: 2005
    ..abstract_text> ..
  29. Hematopoietic Lineage-restricted Minor Histocompatibility Antigens as GVL Targets
    Anthony G Brickner; Fiscal Year: 2010
    ..3) To assess the natural cell-surface expression of the candidate mHAg peptides, and to validate their hematopoietic-restricted expression at the cellular and RNA levels. ..